World Library  
Flag as Inappropriate
Email this Article

Cold agglutinin disease

Article Id: WHEBN0004517757
Reproduction Date:

Title: Cold agglutinin disease  
Author: World Heritage Encyclopedia
Language: English
Subject: Hematologic disease, Hemagglutinin, Nutritional anemia, Delta-thalassemia, Hexokinase deficiency
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Cold agglutinin disease

Cold agglutinin disease
Classification and external resources
Cold agglutination - at body temperature, the antibodies do not attach to the red blood cells. At lower temperatures, however, the antibodies react to Ii antigens, bringing the red blood cells together, a process known as agglutination
ICD-10 D59.1
ICD-9 283.0
DiseasesDB 2949
eMedicine med/408
MeSH D000744

Cold agglutinin disease is an autoimmune disease characterized by the presence of high concentrations of circulating antibodies, usually IgM, directed against red blood cells.[1] It is a form of autoimmune hemolytic anemia, specifically one in which antibodies only bind red blood cells at low body temperatures, typically 28-31 °C.

It was first described in 1957.[2][3]

Etiology

There are two forms of cold agglutinin disease: 1-primary and 2-secondary.

  • The primary form is by definition idiopathic, a disease for which no cause is known.[4]

Pathophysiology

All individuals have circulating antibodies directed against red blood cells, but their concentrations are often too low to trigger disease (titers under 64 at 4 °C). In individuals with cold agglutinin disease, these antibodies are in much higher concentrations (titers over 1000 at 4 °C).

At body temperatures of 28-31 °C, such as those encountered during winter months, and occasionally at body temperatures of 37 °C, antibodies (generally IgM) bind to the polysaccharide region of glycoproteins on the surface of red blood cells (typically the I antigen, i antigen, and Pr antigens). Binding of antibodies to red blood cells activates the classical pathway of the complement system. If the complement response is sufficient, red blood cells are damaged by the membrane attack complex, an effector of the complement cascade. In the formation of the membrane attack complex, several complement proteins are inserted into the red blood cell membrane, forming pores that lead to membrane instability and intravascular hemolysis (destruction of the red blood cell within the blood vessels).

If the complement response is insufficient to form membrane attack complexes, then extravascular lysis will be favored over intravascular red blood cell lysis. In lieu of the membrane attack complex, complement proteins (particularly C3b and C4b) are deposited on red blood cells. This opsonization enhances the clearance of red blood cell by phagocytes in the liver, spleen, and lungs, a process termed extravascular hemolysis.

Individuals with cold agglutinin disease present with signs and symptoms of hemolytic anemia. Those with secondary agglutinin disease may also present with an underlying disease, often autoimmune.

Treatment

  • Avoid cold weather.
  • Treat the underlying lymphoma.
  • No cold drinks, all drinks should be on normal temperature.
  • Requires Heater to maintain temperature in cold places.

Treatment with rituximab has been described.[5]

See also

References

  1. ^ "Cold Agglutinin Disease: Overview - eMedicine Pediatrics: General Medicine". Retrieved 2009-02-07. 
  2. ^ Gertz MA (April 2006). "Cold agglutinin disease". Haematologica 91 (4): 439–41.  
  3. ^ DACIE JV, CROOKSTON JH, CHRISTENSON WN (January 1957). "Incomplete cold antibodies role of complement in sensitization to antiglobulin serum by potentially haemolytic antibodies". Br. J. Haematol. 3 (1): 77–87.  
  4. ^ Berentsen S, Beiske K, Tjønnfjord GE (October 2007). "Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy". Hematology 12 (5): 361–70.  
  5. ^ Berentsen S, Ulvestad E, Gjertsen BT, et al. (April 2004). "Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients". Blood 103 (8): 2925–8.  
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.